NCT02194231 - ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) | Biotech Hunter

Enrollment

145

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 12, 2019

Study Completion Date

December 12, 2019

Conditions

Malignant Pleural Mesothelioma

Interventions

DRUG

Trabectedin

Patients will receive 1.1 mg/m2 intravenous trabectedin infusion in 5% glucose via central venous catheter over 3 hours every 21 days. Trabectedin infusion will be preceded by 20 mg of intravenous dexamethasone

Trial Locations (8)

20089

Istituto Clinico Humanitas, Rozzano

20900

Azienda Ospedaliera S. Gerardo di Monza, Monza

25125

P.O. Spedalli Civili, Brescia

35128

Istituto Oncologico Veneto - IOV, Padua

40138

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna

43126

Azienda Ospedaliro-Universitaria di Parma, Parma

Unknown

Azienda ospedaliera ss. Antonio e Biagio e Cesare Arrigo, Alessandria

Cliniche Humanitas Gavazzeni, Bergamo